MedTrace Logo

Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease

NCT00967993 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2014-12-05

Study results available
· View outcomes & findings →

Summary

The objective of this study is to see if KRX-0502 (ferric citrate) is safe and effective as a dietary phosphate binder in controlling and managing serum phosphorus levels in patients with end-stage renal disease (ESRD).

Conditions

  • Hyperphosphatemia
  • End-stage Renal Disease
  • Renal Failure Chronic Requiring Hemodialysis

Interventions

DRUG

ferric citrate

KRX-0502 will be supplied as one caplet of ferric citrate containing 210 mg of ferric iron as ferric citrate

Sponsors & Collaborators

  • Keryx Biopharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Itamar Raz, MD · Hadassah University Hospital-Ein Kerem

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00967993 on ClinicalTrials.gov